Assessment of LBR-101 In Chronic Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions
Chronic Migraine
Interventions
DRUG

LBR-101 High Dose

Subcutaneously Administered LBR-101 Monthly x 3

DRUG

LBR-101 Low Dose

Subcutaneously Administered LBR-101 Monthly x 3

DRUG

Placebo

Subcutaneously Administered Placebo (Vehicle) Monthly x 3

Trial Locations (57)

10461

Teva Investigational Site 105, The Bronx

19107

Teva Investigational Site 111, Philadelphia

22911

Teva Investigational Site 123, Charlottesville

24018

Teva Investigational Site 144, Roanoke

27103

Teva Investigational Site 168, Winston-Salem

27607

Teva Investigational Site 118, Raleigh

29445

Teva Investigational Site 120, Goose Creek

30030

Teva Investigational Site 164, Decatur

30134

Teva Investigational Site 134, Douglasville

30342

Teva Investigational Site 149, Atlanta

32127

Teva Investigational Site 140, Port Orange

32174

Teva Investigational Site 139, Ormond Beach

32216

Teva Investigational Site 101, Jacksonville

32256

Teva Investigational Site 166, Jacksonville

32720

Teva Investigational Site 143, DeLand

32751

Teva Investigational Site 129, Maitland

32801

Teva Investigational Site 167, Orlando

33012

Teva Investigational Site 137, Hialeah

37203

Teva Investigational Site 154, Nashville

37620

Teva Investigational Site 153, Bristol

38119

Teva Investigational Site 126, Memphis

43221

Teva Investigational Site 102, Columbus

44195

Teva Investigational Site 155, Cleveland

44718

Teva Investigational Site 122, Canton

45227

Teva Investigational Site 141, Cincinnati

47714

Teva Investigational Site 125, Evansville

48104

Teva Investigational Site 110, Ann Arbor

49009

Teva Investigational Site 114, Kalamazoo

55422

Teva Investigational Site 150, Golden Valley

63141

Teva Investigational Site 104, St Louis

64114

Teva Investigational Site 152, Kansas City

65807

Teva Investigational Site 107, Springfield

66214

Teva Investigational Site 133, Lenexa

73112

Teva Investigational Site 127, Oklahoma City

76012

Teva Investigational Site 128, Arlington

78731

Teva Investigational Site 121, Austin

78745

Teva Investigational Site 136, Austin

80304

Teva Investigational Site 132, Boulder

85032

Teva Investigational Site 130, Phoenix

85234

Teva Investigational Site 145, Gilbert

85259

Teva Investigational Site 117, Scottsdale

89502

Teva Investigational Site 148, Reno

90806

Teva Investigational Site 119, Long Beach

92056

Teva Investigational Site 146, Oceanside

92801

Teva Investigational Site 161, Anaheim

92835

Teva Investigational Site 116, Fullerton

94109

Teva Investigational Site 113, San Francisco

94305

Teva Investigational Site 108, Stanford

94598

Teva Investigational Site 112, Walnut Creek

06905

Teva Investigational Site 162, Stamford

02301

Teva Investigational Site 135, Brockton

02740

Teva Investigational Site 124, New Bedford

01104

Teva Investigational Site 151, Springfield

02472

Teva Investigational Site 109, Watertown

01605

Teva Investigational Site 115, Worcester

27405-6962

Teva Investigational Site 131, Greensboro

45229-3039

Teva Investigational Site 142, Cincinnati

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02021773 - Assessment of LBR-101 In Chronic Migraine | Biotech Hunter | Biotech Hunter